Castle Biosciences Stock Performance
| CSTL Stock | USD 29.51 0.30 1.01% |
Castle Biosciences has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.19, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Castle Biosciences will likely underperform. Castle Biosciences right now shows a risk of 3.24%. Please confirm Castle Biosciences value at risk, as well as the relationship between the skewness and day median price , to decide if Castle Biosciences will be following its price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Castle Biosciences are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite quite persistent basic indicators, Castle Biosciences is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors. ...more
Actual Historical Performance (%)
One Day Return 4.88 | Five Day Return 8.37 | Year To Date Return 40.94 | Ten Year Return 44.63 | All Time Return 44.63 |
1 | Disposition of 1250 shares by Oelschlager Kristen M of Castle Biosciences at 29.969 subject to Rule 16b-3 | 09/03/2024 |
2 | Disposition of tradable shares by Derek Maetzold of Castle Biosciences at 30.024 subject to Rule 16b-3 | 09/04/2024 |
3 | Disposition of 150 shares by Derek Maetzold of Castle Biosciences at 29.457 subject to Rule 16b-3 | 09/09/2024 |
4 | New Data at ASTRO 2024 Shows Castle Biosciences DecisionDx-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatm... | 09/27/2024 |
5 | Disposition of 150 shares by Derek Maetzold of Castle Biosciences at 28.734 subject to Rule 16b-3 | 10/04/2024 |
6 | Castle Biosciences CEO Derek Maetzold sells stock for 165,463 | 10/16/2024 |
7 | Acquisition by Olson Tiffany of 830 shares of Castle Biosciences subject to Rule 16b-3 | 10/21/2024 |
8 | Castle Biosciences, Inc. Q3 2024 Earnings Call Transcript | 11/05/2024 |
9 | Disposition of 934 shares by Derek Maetzold of Castle Biosciences at 32.528 subject to Rule 16b-3 | 11/06/2024 |
10 | Castle Biosciences Upgraded to Strong Buy Heres Why | 11/07/2024 |
11 | Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx-Melanoma and MyPath Melanoma at the American Society of Dermatopathol... | 11/08/2024 |
12 | Disposition of 299 shares by Derek Maetzold of Castle Biosciences at 34.15 subject to Rule 16b-3 | 11/12/2024 |
13 | Novavax Q3 Earnings Sales Beat, Stock Falls 6 percent on 24 View Cut | 11/13/2024 |
14 | RNA Stock Hits Record High on Entering the Cardiac Disease Space | 11/14/2024 |
15 | Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year | 11/19/2024 |
16 | Castle Biosciences Inc Stock Price Down 3.36 percent on Nov 20 | 11/20/2024 |
17 | Are Medical Stocks Lagging AnaptysBio This Year | 11/25/2024 |
| Begin Period Cash Flow | 122.9 M |
Castle |
Castle Biosciences Relative Risk vs. Return Landscape
If you would invest 2,863 in Castle Biosciences on August 28, 2024 and sell it today you would earn a total of 88.00 from holding Castle Biosciences or generate 3.07% return on investment over 90 days. Castle Biosciences is currently generating 0.0985% in daily expected returns and assumes 3.24% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Castle, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Castle Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Castle Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Castle Biosciences, and traders can use it to determine the average amount a Castle Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0304
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | CSTL | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.24 actual daily | 28 72% of assets are more volatile |
Expected Return
| 0.1 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Castle Biosciences is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Castle Biosciences by adding it to a well-diversified portfolio.
Castle Biosciences Fundamentals Growth
Castle Stock prices reflect investors' perceptions of the future prospects and financial health of Castle Biosciences, and Castle Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Castle Stock performance.
| Return On Equity | 0.0147 | ||||
| Return On Asset | -0.0014 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 581.85 M | ||||
| Shares Outstanding | 28.01 M | ||||
| Price To Earning | 87.86 X | ||||
| Price To Book | 1.89 X | ||||
| Price To Sales | 2.68 X | ||||
| Revenue | 219.79 M | ||||
| Gross Profit | 105.03 M | ||||
| EBITDA | (45.02 M) | ||||
| Net Income | (57.47 M) | ||||
| Cash And Equivalents | 273.17 M | ||||
| Cash Per Share | 10.39 X | ||||
| Total Debt | 15.34 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 11.08 X | ||||
| Book Value Per Share | 15.77 X | ||||
| Cash Flow From Operations | (5.63 M) | ||||
| Earnings Per Share | 0.21 X | ||||
| Market Capitalization | 834.9 M | ||||
| Total Asset | 453.34 M | ||||
| Retained Earnings | (218.37 M) | ||||
| Working Capital | 247.97 M | ||||
| Current Asset | 125.89 M | ||||
| Current Liabilities | 13.31 M | ||||
About Castle Biosciences Performance
By examining Castle Biosciences' fundamental ratios, stakeholders can obtain critical insights into Castle Biosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Castle Biosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 64.44 | 44.02 | |
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.17) | (0.18) | |
| Return On Assets | (0.13) | (0.13) | |
| Return On Equity | (0.15) | (0.14) |
Things to note about Castle Biosciences performance evaluation
Checking the ongoing alerts about Castle Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Castle Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Castle Biosciences had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 219.79 M. Net Loss for the year was (57.47 M) with profit before overhead, payroll, taxes, and interest of 105.03 M. | |
| Castle Biosciences currently holds about 273.17 M in cash with (5.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.39. | |
| Castle Biosciences has a poor financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Are Medical Stocks Lagging AnaptysBio This Year |
- Analyzing Castle Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Castle Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Castle Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Castle Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Castle Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Castle Biosciences' stock. These opinions can provide insight into Castle Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share 0.21 | Revenue Per Share 11.34 | Quarterly Revenue Growth 0.395 | Return On Assets (0) |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.